Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 586,562 shares of the biopharmaceutical company’s stock after selling 2,391 shares during the period. Dimensional Fund Advisors LP owned 0.53% of Regeneron Pharmaceuticals worth $616,498,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. West Paces Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $26,000. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.0 %

Shares of REGN opened at $1,153.35 on Monday. The firm’s 50-day moving average is $1,124.22 and its two-hundred day moving average is $1,026.46. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $127.08 billion, a P/E ratio of 34.07, a PEG ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $8.79 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. Argus raised their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,109.70.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock worth $11,498,705 in the last three months. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.